J&J Topamax Letter Recommends Monitoring For Decreased Sweating

A warning added to Johnson & Johnson's anti-convulsant Topamax (topiramate) is in line with a label revision for Elan's anti-convulsant Zonegran stating that patients should be closely monitored for decreased sweating and increased body temperature